Cholelithiasis News and Research

RSS

How does the gut microbiome affect muscle strength?

Researchers use fecal microbiome transplantation in mouse models to examine the role of gut microbiota in determining muscle strength.

14 Mar 2023

Metabolomic study of genetic regulation of biochemical individuality

Researchers systematically investigated the genetic makeup of nearly 20,000 women and men in terms of >900 metabolites.

15 Nov 2022

Scientific review highlights the impact of coffee on digestive organs

A new scientific review, published in Nutrients, highlights coffee's effects on digestion and the gut, and its impact on organs involved in digestion.

19 Jan 2022

Gallstones, statins increase risk of acute pancreatitis, shows study

Idiopathic pancreatitis is often caused by small gallstones that are difficult to observe prior to surgery, shows a study from the University of Eastern Finland. Small gallstones were found in surgery from two out of three idiopathic pancreatitis patients.

8 Dec 2015

FDA approves Novo Nordisk’s weight loss injection, Saxenda

Novo Nordisk today announced that the Food and Drug Administration (FDA) has approved the new drug application (NDA) for Saxenda® (liraglutide [rDNA origin] injection), the first once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management.

25 Dec 2014

Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announced today that the US Food and Drug Administration has approved Signifor long-acting release (LAR) (pasireotide) for injectable suspension, for intramuscular use, for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option.

16 Dec 2014

Researchers recommend laparoscopic surgical removal of gallbladder for pediatric patients

A recent study conducted by Mayo Clinic researchers recommends laparoscopic cholecystectomies (surgical removal of the gallbladder) for pediatric patients suffering from gallstones and other gallbladder diseases.

8 Aug 2014

Ipsen submits Supplemental New Drug Application to FDA for Somatuline Depot 120mg injection

Ipsen today announced that it has submitted a Supplemental New Drug Application to the U.S. Food and Drug Administration for Somatuline Depot 120mg injection for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

1 Jul 2014

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Novartis today presented results from a pivotal Phase III trial of investigational therapy Signifor® LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of care provides inadequate disease control.

6 May 2014

Synageva BioPharma reports study results of sebelipase alfa in adults with late onset LAL Deficiency

Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, today reported 12-month results from an ongoing extension study with sebelipase alfa in adults with late onset Lysosomal Acid Lipase Deficiency.

9 May 2013

Synageva announces 12-week data from sebelipase alfa Phase I/II study on LAL Deficiency

Synageva BioPharma Corp. (Synageva), a clinical stage biopharmaceutical company developing therapeutic products for rare diseases, today announced publication of the 12-week Phase I/II extension study data of sebelipase alfa in adults with lysosomal acid lipase deficiency (LAL Deficiency) in the online version and an upcoming print edition of Hepatology

5 Feb 2013

FDA approves Novartis Signifor injection for treatment of Cushing's disease

Novartis announced today that the US Food and Drug Administration (FDA) has approved Signifor (pasireotide) injection for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.

14 Dec 2012

FDA EMDAC votes unanimously in support of Signifor use for treatment of Cushing's disease

The US Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has voted unanimously in support of the use of Signifor (pasireotide) for the treatment of patients with Cushing's disease who require medical therapeutic intervention.

7 Nov 2012

Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA

Amgen and Pfizer Inc. today announced results from a new trial that demonstrated Enbrel significantly improved scalp involvement in adult patients with moderate to severe plaque psoriasis, compared with placebo. The data will be presented today at the 69th Annual American Academy of Dermatology meeting in New Orleans, La.

5 Feb 2011

VYTORIN reduces major vascular events in patients with chronic kidney disease

In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck, VYTORIN 10/20 mg reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo, Study of Heart and Renal Protection study involved more than 9,000 patients who, on average, had advanced or end-stage chronic kidney disease (CKD)

22 Nov 2010

Novartis' SOM230 reduces cortisol levels in Cushing's disease patients

Novartis Pharmaceuticals Corporation announced today that the results of a Phase III study of SOM230 (pasireotide) showed a reduction in cortisol levels in patients with Cushing's disease, a condition in which a benign (non-cancerous) pituitary tumor causes the adrenal glands to produce excess cortisol and can be fatal. Results will be presented at the 14th Congress of the European Neuroendocrine Association (ENEA).

22 Sep 2010

Research indicates that acute hepatocellular injury in cholelithiasis and cholecystitis without choledocholithiasis is mild and transient

Acute hepatocellular injury is a commonly encountered phenomenon in patients with cholelithiasis and concomitant common bile duct (CBD) stones. However, in clinical practice, it seemed to occur also in cholelithiasis patients without evidence of CBD stones. Its incidence and final outcome necessitated clarification.

26 Aug 2009

Nanobac announces Baylor initial results for nanoparticle and gall stone formation study

Nanobac Pharmaceuticals Inc has announced that scientists at the Baylor College of Medicine, working under a collaborative agreement with Nanobac, have cited evidence showing the presence of calcifying nanoparticles (CNPs) in surgically resected gallbladders with cholelithiasis (Gall Stones).

15 Jan 2008

Estrogen therapy may increase risk for gallbladder disease

Dominic J. Cirillo, B.S., of the University of Iowa, Iowa City, and colleagues examined data from the Women’s Health Initiative (WHI), which were two randomized, double-blind, placebo-controlled trials conducted at 40 U.S. clinical centers.

19 Jan 2005